<DOC>
	<DOCNO>NCT00305617</DOCNO>
	<brief_summary>RATIONALE : Determining whether erlotinib pass cerebrospinal fluid may help plan treatment type cancer . PURPOSE : This clinical trial study well erlotinib able pas cerebrospinal fluid patient receive erlotinib stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Cerebrospinal Fluid Levels Erlotinib Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine cerebrospinal fluid penetration erlotinib subset patient undergoing treatment erlotinib stage III non-small cell lung cancer CNS metastatic disease . OUTLINE : This pilot , nonrandomized study . Patients undergo single lumbar puncture ( LP ) remove cerebrospinal fluid analysis . After completion study , patient monitor 1 month LP assess LP-related complication . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must enrol trial : `` A Phase I/II Trial Neoadjuvant Paclitaxel , Carboplatin OSI774 ( Tarceva ) Concurrent Accelerated Hyperfractionation Radiation Followed Maintenance Therapy OSI774 Stage III NonSmall Cell Lung Cancer , '' Principal Investigator : T. Mekhail , M.D . Patient must maintenance therapy phase study receive erlotinib ≥ 1 week No know CNS primary metastatic cancer time prior time enrollment No MRI evidence pathological enhancement time study entry PATIENT CHARACTERISTICS : Patients must use adequate birth control measure study No significant side effect erlotinib require dose reduction interruption None follow medical issue could make lumbar puncture unsafe : Platelets &lt; 100,000/mm³ INR &gt; 1.1 Known bleeding dyscrasia Absolute neutrophil count &lt; 1,500/mm³ Ongoing systemic bacterial infection PRIOR CONCURRENT THERAPY : Patients modest antiepileptic therapy must nonenzymeinducing drug , include follow : Neurontin Lamictal Depakote , Depakene Felbatol Keppra Gabitril Topimax Zonegran No concurrent enzymeinducing antiepileptic drug phenytoin , carbamazepine , phenobarbital No concurrent drug know affect metabolism erlotinib No concurrent anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>